Article
Primary Prevention and Interception Studies in RAS-Mutated Tumor Models Employing Small Molecules or Vaccines.
Cancer prevention research (Philadelphia, Pa.) - 2 Oct 2023
Dragnev Konstantin H, Lubet Ronald A, Miller Mark Steven, Sei Shizuko, Fox Jennifer T, You Ming
Abstract excerpt
Therapeutic targeting of RAS-mutated cancers is difficult, whereas prevention or interception (treatment before or in the presence of preinvasive lesions) preclinically has proven easier. In the A/J mouse lung model, where different carcinogens induce tumors with different KRAS mutations, glucocorticoids and retinoid X receptor (RXR) agonists are effective agents in prevention and interception studies,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.